Prognostic value of paraoxonase 1 in patients undergoing coronary artery bypass grafting surgery

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 594-600

  Wysocka, Anna ^a   Cybulski, Marek ^a   Berbeć, Henryk ^a   Wysokiński, Andrzej ^a   Stazka, Janusz ^a   Zapolski, Tomasz ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Aryldialkylphosphatase; Coronary artery bypass; Coronary artery disease

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARAOXON; PHENYLACETIC ACID; TRIACYLGLYCEROL; BERBERINE; CYTOCHROME P450 3A4; GAMMA ORYZANOL; LIVER ENZYME; MONACOLIN L; NUTRACEUTICAL; POLICOSANOL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BODY MASS; CORONARY ARTERY BYPASS SURGERY; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENOTYPE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION SYSTEM; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HYPOCHOLESTEROLEMIA; LIPID METABOLISM; MORTALITY; TREATMENT OUTCOME;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; CORONARY ARTERY BYPASS; CORONARY DISEASE; DEMOGRAPHY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 84898403128     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.890025     Document Type: Article

References (21)

1. Harel M, Aharoni A, Gaidukov L et al: Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol, 2004; 11: 412-19
2. Shih DM, Gu L, Xia YR et al: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature, 1998; 394: 284-87
3. Mackness M, Mackness B: Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic Biol Med, 2004; 37: 1317-23
4. Sanghera DK, Aston CE, Saha N, Kamboh MI: DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet, 1998; 62: 36-44
5. Agrawal S, Tripathi G, Prajnya R et al: Paraoxonase 1 gene polymorphisms contribute to coronary artery disaese risk among north Indians. Indian J Med Sci, 2009; 63: 335-44
6. Gluba A, Pietrucha T, Banach M et al: The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311 Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology, 2010; 61: 157-65
7. Deakin S, Leviev I, Brulhart Meynet MC, James RW: Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role in vivo for polymorphic position - 107 implicating the transcriptionfactor Sp 1. Biochem J, 2003; 372: 643-49
8. Pokrovsky SN, Ezhov MV, Ilina LN et al: Association of lipoprotein (a) excess with early vein graft occlusions in middle aged men undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg, 2003; 126: 1071-75
9. Campeau L: Letter. Grading of angina pectoris. Circulation, 1976; 54: 522-23
10. Braunwald E: Unstable angina: a classification. Circulation, 1989; 80: 410-14
11. Eckerson H, Romson WJ, Wyte C, La Du B: The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet, 1983; 35: 214-27
12. Brophy VH, Jampsa RL, Clendenning JB et al: Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet, 2001; 68: 1428-36
13. Friedwald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502
14. Wang M, Lang X, Zou L et al: Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: A meta-analysis based on 88 casecontrol studies. Atherosclerosis, 2011; 214: 377-85
15. Wheeler JG, Keavney BD, Watkins H et al: Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta- analysis of 43 studies. Lancet, 2004; 363: 689-95
16. Mackness B, Durrington P, McElduff P et al: Low paraoxonase activity predicts coronary events in the Caerphilly prospective study. Circulation, 2003; 107: 2775-79
17. Kurban S, Mehmetoglu I, Ege E: Effects of preoperative atorvastatin therapy on paraoxonase activity and oxidative stress after coronary artery bypass grafting. Perfusion, 2009; 24: 271-76
18. Linden T, Taddei-Peters W, Wilhelmsen L et al: Serum lipids, lipoprotein (a) and apo (a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary bypass surgery. Atherosclerosis, 1998; 137: 175-86
19. De Rijke Y, Verwey HF, Vogelezang CJ et al: Enhanced susceptibility of lowdensity lipoproteins to oxidation in coronary bypass patients with progression of atheroscerosis. Clin Chem Acta, 1995; 243: 137-49
20. Kumon Y, Suehiro T, Ikeda Y, Hashimoto K: Human paraoxonase-1 gene expression by Hep G2 cells is downregulated by interleukin-1b and tumor necrosis factor-a, but is upregulated by interleukione-6. Life Sciences 2003; 73: 2807-2815,
21. Luyten CR, van Overveld FJ, De Backer LA et al: Antioxidant defence during cardiopulmonary bypass surgery. Eur J Cardiothorac Surg, 2005; 27: 611-16